Detalle Publicación

ARTÍCULO
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Autores: Rodríguez Otero, Paula; Mateos, M. V.; Martinez-Lopez, J.; Martín Calvo, Nerea; Hernandez, M. T.; Ocio, E. M.; Rosinol, L. ; Martinez, R. ; Teruel, A. I. ; Gutierrez, N. C.; Bargay, J.; Bengoechea, E.; Gonzalez, Y. ; de Oteyza, J. P.; Gironella, M. ; Encinas, C.; Martin, J.; Cabrera, C. ; Palomera, L.; de Arriba, F.; Cedena, M. T.; Paiva, Bruno; Puig, N.; Oriol, A.; Blade, J.; Lahuerta, J. J.; San Miguel Izquierdo, Jesús (Autor de correspondencia)
Título de la revista: LEUKEMIA
ISSN: 0887-6924
Volumen: 32
Número: 11
Páginas: 2427 - 2434
Fecha de publicación: 2018
Lugar: WOS
Resumen:
Although survival of elderly myeloma patients has significantly improved there is still a subset of patients who, despite being fit and achieving optimal responses, will die within 2 years of diagnosis due to myeloma progression. The objective of this study was to define a scoring prognostic index to identify this group of patients. We have evaluated the outcome of 490 newly diagnosed elderly myeloma patients included in two Spanish trials (GEM2005-GEM2010). Sixty-eight patients (13.8%) died within 2 years of diagnosis (early deaths) due to myeloma progression. Our study shows that the use of simple scoring model based on 4 widely available markers (elevated LDH, ISS 3, high risk CA or >75 years) can contribute to identify up-front these patients. Moreover, unsustained response (<6 months duration) emerged as one important predictor of early myeloma-related mortality associated with a significant increase in the risk of death related to myeloma progression. The identification of these patients at high risk of early death is relevant for innovative trials aiming to maintain the depth of first response, since many of them will not receive subsequent lines of therapy.